http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Trading Radar for 7/26: Apple (AAPL), McDonald's (MCD), 3M (MMM), Caterpillar (CAT), Verizon (VZ), [Conference Call] Under Armour (UA) Report
-
Eli Lilly & Co. (LLY) Announces FDA Approval of Expanded Synjardy Indication
-
U.S. FDA expands indication for type 2 diabetes treatment Synjardy® (empagliflozin/metformin hydrochloride) to include treatment-naïve adults
-
2016 INVESTIndiana Equity Conference Announces Corporate Presentation Lineup
-
Lilly Diabetes Welcomes Acclaimed Singer/Songwriter Crystal Bowersox as Newest Spokesperson
-
FDA Advisory Committee recommends approval of Jardiance® (empagliflozin) for cardiovascular indication in 12-11 vote
-
Diabetes Scholars Foundation Announces 2016 Scholarship Recipients
-
Lilly (LLY), Boehringer Ingelheim Announce Publication of Clinically Important Jardiance Data in Reducing Kidney Disease in T2D
-
Jardiance® (empagliflozin) significantly reduced the risk of progressive kidney disease in adults with type 2 diabetes with established cardiovascular disease
-
Eli Lilly & Co. (LLY) Announces Significant Data from Trulicity Combo Phase 3 in T2D Glycemic Control
-
New Data Show Lilly's Once-Weekly Trulicity® (dulaglutide) in Combination with Insulin Glargine Improves Glycemic Control in People with Type 2 Diabetes
-
New Jardiance® (empagliflozin) data show that reduced risk for cardiovascular (CV) death was consistent across age groups in adults with type 2 diabetes
-
New Study Findings Underscore Importance of Physician/Patient Communication on Insulin Adherence and Outcomes
-
New study results show Tradjenta® (linagliptin) reduces blood sugar in adults with type 2 diabetes at risk for kidney impairment
-
Eli Lilly & Co. (LLY), Incyte (INCY) Report Baricitinib Superiority to Placebo in Inhibiting RA-Related Joint Damage
-
Eli Lilly & Co. (LLY), Incyte (INCY) Announce Significant Data from Two Baricitinib Phase 3s in RA
-
Patient-reported outcomes across phase 3 studies of baricitinib demonstrate statistically significant improvements in physical function and quality of life symptoms in patients with rheumatoid arthrit
-
Baricitinib significantly reduces joint damage progression in rheumatoid arthritis in patients who do not respond to conventional DMARDs
-
Boehringer Ingelheim and Lilly's (LLY) Jentadueto XR Approved by U.S. FDA
-
U.S. FDA Approves Once-daily Jentadueto® XR (linagliptin and metformin hydrochloride extended-release) Tablets for Adults with Type 2 Diabetes
-
Largest Independent U.S. Psoriasis Registry to Track Safety of New Biologic Treatment
-
Trading Radar for 4/26: Apple (AAPL), Chipotle (CMG), Twitter (TWTR), 3M ((MMM), Procter & Gamble (PG), Freeport-McMoRan (FCX) Report
-
Jardiance® (empagliflozin) to be studied for the treatment of people with chronic heart failure
-
Incyte (INCY) Acquires Jakafi Commercialization, Development Rights from Lilly (LLY)
-
Incyte Acquires Rights from Lilly to Develop and Commercialize Ruxolitinib (Jakafi®) for the Treatment of Patients with Graft-Versus-Host Disease (GVHD)
-
Lilly Diabetes Helps Inspiring Students with Type 1 Diabetes Attend College Through Scholarship Donation
-
American Diabetes Association® Survey Shows Summer Camp Can Positively Impact Children's Disease Management Skills, Confidence and Stress
-
FDA Accepts Eli Lilly & Co. (LLY) sNDA for Jardiance Cardiovascular Outcomes Data
-
U.S. FDA Accepts Filing of Cardiovascular Outcomes Data for Jardiance® (empagliflozin)
-
Market Wrap: U.S. Auto Sales Have Banner Year; Twitter Said Mulling Key Character-Limit Initiative
-
FDA Approves Basaglar® (insulin glargine injection), a Long-Acting Insulin Treatment
-
Eli Lilly & Co. (LLY), Merck (MRK) Enter Collaboration for Abemaciclib Phase 1
-
Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA® Combination Trial
-
Lilly and Merck Expand Immuno-oncology Collaboration with Phase III Nonsquamous Non-Small Cell Lung Cancer Trial
-
New Jardiance® (empagliflozin) data show improved CV outcomes regardless of heart failure status at baseline
-
EMPA-REG OUTCOME®: Top-line renal data to be presented during American Society of Nephrology (ASN) Kidney Week 2015
-
Lilly Diabetes and NASCAR XFINITY Series Driver Ryan Reed Announce Winners of the My Diabetes Pit Crew Sweepstakes
-
Top 10 News for 10/9 - 10/16: Dell's Big Buy; Wal-mart's Dire Outlook; Twitter's Busy Week; Square's Imminent IPO
-
New Type 2 Diabetes Treatment Synjardy® (empagliflozin/metformin hydrochloride) Tablets Now Available in U.S. Pharmacies
-
Pre-Open Stock Movers 10/12: (ESPR) (OREX) (EMC) Higher; (MHR) (SIEN) (LLY) Lower (more...)
-
Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial
-
U.S. FDA approves Synjardy® (empagliflozin/metformin hydrochloride) tablets for adults with type 2 diabetes
-
Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events
-
Lilly's Humalog® 200 units/mL KwikPen® Now Available in U.S. Pharmacies
-
Lilly Diabetes and NASCAR XFINITY Series Driver Ryan Reed Want You to Think About Your Diabetes Pit Crew
-
Lilly Diabetes Launches Android Version of Glucagon Mobile Application for Those Who Support People with Diabetes
-
Diabetes Scholars Foundation Announces 2015 Scholarship Recipients
-
Olympian Kris Freeman and NASCAR Driver Ryan Reed to Share Their Courageous Stories with Children Who Have Type 1 Diabetes
-
U.S. Food and Drug Administration Approves Humalog® 200 units/mL KwikPen®
-
Boehringer Ingelheim and Lilly Diabetes Alliance to Present Data from 35 Studies at the American Diabetes Association's 75th Scientific Sessions®

